MSH2 and Lynch syndrome: Increased risk of upper-tract urothelial cancer has been reported in Lynch syndrome (LS), as well as increased risk of bladder cancer.67,68 The estimated risk of urothelial cancer in LS is 5%–20%, with risk increasing in males and MSH2 mutation carriers.